Indeed, ISB 1442 induced killing of tumor cells in patient samples was superior to that of daratumumab and was significantly higher in samples from patients that relapsed from the anti-CD38 therapy; these observations suggest that ISB 1442 could be used as a salvage therapy. Here, CD38 is linked to neoplasm.